Subscribe To
IVA / Inventiva: An Untenable Cash Position Despite Enviable Data
IVA News
By Seeking Alpha
July 16, 2023
Inventiva: An Untenable Cash Position Despite Enviable Data
IVA has robust data from a mid-stage NASH trial. They have an ongoing pivotal study running, to topline in H2 2025. They don't have enough cash to com more_horizontal
By Seeking Alpha
March 30, 2023
Inventiva S.A. (IVA) 2022 Full Year Results Earnings Call Transcript
Inventiva S.A. (NASDAQ:IVA ) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief more_horizontal
By Zacks Investment Research
September 8, 2022
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal
By GlobeNewsWire
June 16, 2022
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Daix (France), Long Island City (New York, United States), June 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceu more_horizontal
By Seeking Alpha
March 8, 2022
Inventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript
Inventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript more_horizontal